

UroLongevity

The Physician's Guide to Healthspan and Precision Aging

Version 2.1 — First Edition
References, Evidence Notes, and Updates

David Shusterman, MD
UroLongevity Press · The Urologist's Guide

Evidence reviewed through August 13, 2026
Bibliography compiled August 14, 2026
Paperback ISBN 979-8-90649-022-3
UroLongevityPress.com/UroLongevity/references

158 references · 49 chapters

This is the frozen publication record of the sources supporting UroLongevity Version 2.1. Corrections and new evidence identified after August 13, 2026 are published separately online and are not included in this file. Citations appear exactly as published; identifiers were extracted only from the supplied source and not independently completed.

Chapter 1. The Body Speaks in Signals

Bliss M. The Discovery of Insulin. University of Chicago Press; 1982. [also cited in Ch. 2]

Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from *Heloderma suspectum* venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. *J Biol Chem* 1992;267:7402-7405. [also cited in Ch. 2]

Merrifield RB. Solid phase peptide synthesis I: The synthesis of a tetrapeptide. *J Am Chem Soc* 1963;85:2149-2154. (Nobel Prize in Chemistry, 1984.) [also cited in Ch. 2]

Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. *Signal Transduct Target Ther* 2022;7:48. [also cited in Ch. 2, 46]

Chapter 3. The Regulatory Landscape — August 2026 Evidence Review

Cohen PA, Bass S. Injecting safety into supplements — modernizing the dietary supplement law. *N Engl J Med* 2019;381:2387-2389. [also cited in Ch. 23, 35, 42]

Drug Quality and Security Act, Pub L No. 113-54 (2013). [also cited in Ch. 42]

Food and Drug Administration. Bulk drug substances used in compounding under section 503A of the FD&C Act: nomination categories and interim enforcement policy. Current agency webpage, accessed August 13, 2026. [Source](#) [also cited in Ch. 42]

Food and Drug Administration. Certain bulk drug substances for use in compounding may present significant safety risks. Current agency webpage, accessed August 13, 2026. [Source](#) [also cited in Ch. 42]

Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Updated through May 31, 2026; accessed August 13, 2026. [Source](#) [also cited in Ch. 42]

Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting materials, including FDA introductory and substance-specific briefing documents for BPC-157, emideltide, epitalon, KPV, MOTS-c, Semax, and TB-500. Accessed August 13, 2026. [Source](#) [also cited in Ch. 17, 18, 20, 22, 23, 42]

Food and Drug Administration. Interim category 2 of the 503A Bulks List. Federal Register, September 29, 2023. [Source](#) [also cited in Ch. 42]

Flagged for editorial review — shown as supplied.

Food and Drug Administration. Removal of certain bulk drug substances from interim category 2 of the 503A Bulks List. Federal Register, April 15, 2026. [Source](#) [also cited in Ch. 42]

Flagged for editorial review — shown as supplied.

Kaeberlein TL, Green AS, Haddad G, et al. Evaluation of off-label rapamycin use to promote healthspan in 333 adults. *GeroScience* 2023;45:2757-2768. [also cited in Ch. 26, 42]

Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. *Bull Exp Biol Med* 2003;135:590-592. [also cited in Ch. 19, 20]

Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. *Neuroendocrinology Letters* 2003;24:233-240. [also cited in Ch. 19, 20]

Outterson K. Regulating compounding pharmacies after NECC. *N Engl J Med* 2012;367:1969-1972. [also cited in Ch. 42]

Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. *Arch Intern Med* 2006;166:1021-1026. [also cited in Ch. 42]

U.S. Department of Justice. Nicholasville compounding pharmacy and its owner plead guilty to unlawful distribution of prescription drugs. Press release, October 5, 2020. (Tailor Made Compounding LLC.) [Source](#) [also cited in Ch. 42]

Flagged for editorial review — shown as supplied.

Chapter 4. Reading the Evidence in a Hype-Saturated Field

Gupta AK, Bamimore MA, Foley KA. Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality. *J Dermatolog Treat* 2022;33:62-72. [also cited in Ch. 38]

Hróbjartsson A, Thomsen ASS, Emanuelsson F, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. *BMJ* 2012;344:e11119.

Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome. *Cochrane Database Syst Rev* 2017;2:MR000033.

Chapter 5. The Biology of Aging

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. *Cell* 2023;186:243-278. [also cited in Ch. 48]

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell* 2013;153:1194-1217. [also cited in Ch. 48]

Ocampo A, Reddy P, Martinez-Redondo P, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. *Cell* 2016;167:1719-1733.e12. [also cited in Ch. 48]

Schmauck-Medina T, Molière A, Lautrup S, et al. New hallmarks of ageing: a 2022 Copenhagen ageing meeting summary. *Aging (Albany NY)* 2022;14:6829-6839. [also cited in Ch. 48]

Chapter 6. Semaglutide: More Than a Weight-Loss Drug

Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. *N Engl J Med* 2025;393:26-36. [also cited in Ch. 7]

Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. *N Engl J Med* 2021;385:503-515. [also cited in Ch. 7]

Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. *N Engl J Med* 2023;389:1069-1084.

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med* 2023;389:2221-2232. [also cited in Ch. 7]

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2016;375:1834-1844.

Novo Nordisk. Evoke and evoke+ trials of oral semaglutide in early Alzheimer's disease did not meet primary endpoint. Press release, November 24, 2025. [Source](#) [also cited in Ch. 37]

Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N Engl J Med* 2024;391:109-121.

Sanyal AJ, Newsome PN, Kliers I, et al; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. *N Engl J Med* 2025;392:2089-2099.

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med* 2021;384:989-1002.

Chapter 7. Tirzepatide: Two Signals, One Powerful Therapy

Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med* 2022;387:205-216. [also cited in Ch. 21]

Malhotra A, Grunstein RR, Fietze I, et al; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. *N Engl J Med* 2024;391:1193-1205. [also cited in Ch. 35]

Nicholls SJ, Bhatt DL, Buse JB, et al; SURPASS-CVOT Investigators. Cardiovascular efficacy and safety of tirzepatide in patients with type 2 diabetes and atherosclerotic cardiovascular disease. *N Engl J Med* 2025;393:2347-2358.

Chapter 8. Liraglutide

Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2016;375:311-322.

Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med* 2015;373:11-22.

Chapter 9. Tesamorelin

Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. *N Engl J Med* 2007;357:2359-2370.

Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. *J Clin Endocrinol Metab* 2010;95:4291-4304.

Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. *J Acquir Immune Defic Syndr* 2010;53:311-322.

Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. *Lancet HIV* 2019;6:e821-e830.

Chapter 10. Elamipretide

Food and Drug Administration. Drug Trials Snapshot: Forzinity (elamipretide). September 2025; accelerated-approval confirmatory study status accessed August 13, 2026. [Source](#)

Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. *Genet Med* 2021;23:471-478. (TAZPOWER trial.)

Stealth BioTherapeutics Inc. Stealth BioTherapeutics announces FDA accelerated approval of Forzinity (elamipretide HCl), the first therapy for progressive and life-limiting ultra-rare genetic disease Barth syndrome. Press release, September 19, 2025. [Source](#)

Chapter 11. PT-141 (Bremelanotide)

Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. *Obstet Gynecol* 2019;134:899-908. (RECONNECT-1 and RECONNECT-2.) [also cited in Ch. 39]

Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. *J Urol* 2008;179:1066-1071. [also cited in Ch. 39]

Simon JA, Kingsberg SA, Goldstein I, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. *Obstet Gynecol* 2019;134:909-917. [also cited in Ch. 39]

Chapter 12. Sermorelin

Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. *J Clin Endocrinol Metab* 1992;75:530-535.

Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH₂ in age-advanced men and women. *J Clin Endocrinol Metab* 1997;82:1472-1479.

Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. *Metabolism* 1997;46:89-96. [also cited in Ch. 29]

Chapter 13. Ipamorelin

Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. *Int J Colorectal Dis* 2014;29:1527-1534.

Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. *Eur J Endocrinol* 1998;139:552-561.

Chapter 14. CJC-1295

Ben-Shlomo A, Deng N, Ding E, et al. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. *J Clin Invest* 2020;130:5738-5755.

Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. *J Clin Endocrinol Metab* 2006;91:4792-4797. [also cited in Ch. 29]

Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. *J Clin Endocrinol Metab* 2006;91:799-805. [also cited in Ch. 29]

Chapter 15. MK-677 (Ibutamoren)

Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. *Arch Gerontol Geriatr* 2011;53:183-189.

Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. *Ann Intern Med* 2008;149:601-611.

Patchett AA, Nargund RP, Tata JR, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. *Proc Natl Acad Sci U S A* 1995;92:7001-7005.

Chapter 16. Thymosin Alpha-1

Goldstein AL, Low TLK, McAdoo M, et al. Thymosin α 1: isolation and sequence analysis of an immunologically active thymic polypeptide. *Proc Natl Acad Sci U S A* 1977;74:725-729. [also cited in Ch. 18]

Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. *Blood* 2004;103:4232-4239.

Zhang YY, Chen EQ, Yang J, et al. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. *Virology* 2009;6:63. [also cited in Ch. 46]

Chapter 17. BPC-157

Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. *J Physiol Paris* 1993;87:313-327.

Talpos S. How a Croatian Lab Spawned a Buzzy Peptide Now Popular With MAHA. *Undark*. February 3, 2026. Co-published by STAT.

McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. *Curr Rev Musculoskelet Med*. 2025;18:611-619. doi:10.1007/s12178-025-09990-7. doi:10.1007/s12178-025-09990-7 · [Source](#)

Chapter 18. TB-500 (Thymosin Beta-4)

Bock-Marquette I, Saxena A, White MD, et al. Thymosin β 4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. *Nature* 2004;432:466-472.

HLB Therapeutics. European Phase 3 SEER-3 topline results for RGN-259 in neurotrophic keratopathy. Company notice, June 24, 2025; independent coverage published July 1, 2025. [Source](#)

Low TLK, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin β 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. *Proc Natl Acad Sci U S A* 1981;78:1162-1166.

Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (Thymosin β 4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. *Int J Mol Sci* 2023;24:554.

Chapter 19. GHK-Cu

Badenhorst T, Svirskis D, Wu Z. Pharmaceutical strategies for the topical dermal delivery of peptides/proteins for cosmetic and therapeutic applications. *Austin J Pharmacol Ther* 2016;4:1083. [also cited in Ch. 40]

Pickart L, Thaler MM. Growth-modulating tripeptide (glycyl-histidyl-lysine): association with copper and iron in plasma, and stimulation of adhesiveness and growth of hepatoma cells in culture by tripeptide-metal ion complexes. *J Cell Physiol* 1980;102:129-139. [also cited in Ch. 40]

Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. *Biomed Res Int* 2015;2015:648108. [also cited in Ch. 40]

Chapter 20. Epitalon

Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. *Biogerontology*. 2025;26:178. doi:10.1007/s10522-025-10315-x. doi:10.1007/s10522-025-10315-x · [Source](#)

Araj M, Brzezick M, M┼dra-Gackowska K, Szeleszczuk ┼. Epitalon — 25 years of research. *Int J Mol Sci* 2025. [Source](#)

Flagged for editorial review — shown as supplied.

Chapter 21. Retatrutide

Eli Lilly and Company. Lilly's retatrutide reduced body weight by 28.7% in adults living with obesity and knee osteoarthritis in pivotal Phase 3 TRIUMPH-4 study. Press release, December 11, 2025. [Source](#)

Jastreboff AM, Kaplan LM, Fr┼as JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. *N Engl J Med* 2023;389:514-526.

Chapter 22. LL-37 and KPV

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. *Gastroenterology* 2008;134:166-178.

Grönberg A, Mahlapuu M, Ståhle M, et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. *Wound Repair Regen* 2014;22:613-621.

Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. *Cell Immunol* 2012;280:22-35.

Chapter 23. MOTS-c

Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. *Cell Metab* 2015;21:443-454.

Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. *Nat Commun* 2021;12:470. [also cited in Ch. 34]

Chapter 24. Orforglipron

Food and Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes (Rybelsus). News release, September 20, 2019. [Source](#)

Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. *Proc Natl Acad Sci U S A* 2020;117:29959-29967.

Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. *N Engl J Med*. 2023;389:877-888. doi:10.1056/NEJMoa2302392. doi:10.1056/NEJMoa2302392 · [Source](#)

Chapter 25. NAD⁺ and Its Precursors

Brakedal B, Dölle C, Riemer F, et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. *Cell Metab* 2022;34:396-407.e6.

Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD⁺ in healthy middle-aged and older adults. *Nat Commun* 2018;9:1286.

McDermott MM, Martens CR, Domanchuk KJ, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. *Nat Commun* 2024;15:5046.

Chapter 26. Rapamycin and the mTOR Pathway

Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. *Cell Metab*. 2016;23:1060-1065. doi:10.1016/j.cmet.2016.05.011. doi:10.1016/j.cmet.2016.05.011 · [Source](#) [also cited in Ch. 48]

Bjedov I, Toivonen JM, Kerr F, et al. Mechanisms of life span extension by rapamycin in the fruit fly *Drosophila melanogaster*. *Cell Metab* 2010;11:35-46. [also cited in Ch. 48]

Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* 2009;460:392-395. [also cited in Ch. 48]

Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. *Sci Transl Med* 2014;6:268ra179. [also cited in Ch. 48]

Mannick JB, Morris M, Hockey HU, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. *Sci Transl Med* 2018;10:eaq1564. [also cited in Ch. 48]

Moel M, Harinath G, Lee V, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. *Aging (Albany NY)* 2025;17:908-936. [also cited in Ch. 48]

Chapter 27. Senolytics — Clearing Senescent Cells

Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. *EBioMedicine* 2019;47:446-456.

Klier S, Dananberg J, Masaki L, et al. Safety and efficacy of senolytic UBX1325 in diabetic macular edema. *NEJM Evidence* 2025;4:EVIDoa2400009.

Schweiger A, Diniz B, Nicol G, et al. Protocol for a pilot clinical trial of the senolytic drug combination dasatinib plus quercetin to mitigate age-related health and cognitive decline in mental disorders. *F1000Res*. 2025;13:1072. doi:10.12688/f1000research.151963.2. doi:10.12688/f1000research.151963.2 · [Source](#) [also cited in Ch. 37, 48]

Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. *Nat Med* 2018;24:1246-1256. [also cited in Ch. 34]

Zhu Y, Tchkonja T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. *Aging Cell* 2015;14:644-658.

Chapter 28. Testosterone

Endocrine Society. Testosterone therapy for hypogonadism guideline resources. Clinical practice guideline, current webpage accessed August 13, 2026. [Source](#)

Endocrine Society. Statement on testosterone replacement therapy. July 16, 2026. [Source](#)

Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. Drug safety communication, February 28, 2025. [Source](#)

Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. *Arch Endocrinol Metab*. 2025;69(5):e250093. doi:10.20945/2359-4292-2025-0093. doi:10.20945/2359-4292-2025-0093 · [Source](#)

Hohl A, Marques P, Ronsoni MF, et al. Selective estrogen receptor modulators (SERMs) for male hypogonadism: a meta-analysis of randomized controlled trials. *Arch Endocrinol Metab* 2025; published online ahead of print.

Flagged for editorial review — shown as supplied.

Lincoff AM, Bhasin S, Flevaris P, et al; TRAVERSE Study Investigators. Cardiovascular safety of testosterone-replacement therapy. *N Engl J Med* 2023;389:107-117.

Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. *N Engl J Med* 2006;355:1647-1659. [also cited in Ch. 32]

Chapter 29. Growth Hormone

Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. *Ann Intern Med* 2007;146:104-115.

Perls TT, Reisman NR, Olshansky SJ. Provision or distribution of growth hormone for “antiaging”: clinical and legal issues. *JAMA* 2005;294:2086-2090.

Chapter 30. Thyroid Hormone

de Lima Beltrão FE, Carvalhal G, de Almeida Beltrão DC, et al. Treatment Preferences in Patients With Hypothyroidism. *J Clin Endocrinol Metab*. 2025;110(3):887-900. doi:10.1210/clinem/dgae651. doi:10.1210/clinem/dgae651 · [Source](#)

Stott DJ, Rodondi N, Kearney PM, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. *N Engl J Med* 2017;376:2534-2544. (TRUST trial.) [also cited in Ch. 47]

Chapter 31. Female Reproductive Hormones — Perimenopause and Menopause

Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. *JAMA* 2013;310:1353-1368.

The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. *Menopause* 2022;29:767-794. [Source](#)

Flagged for editorial review — shown as supplied.

Chapter 32. DHEA and Adrenal Steroids

Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2016;101:364-389.

Chapter 33. The Integration Framework

Kokkinos P, Faselis C, Samuel IBH, et al. Cardiorespiratory fitness and mortality risk across the spectra of age, race, and sex. *J Am Coll Cardiol* 2022;80:598-609. [also cited in Ch. 34]

Mandsager K, Harb S, Cremer P, et al. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. *JAMA Netw Open* 2018;1:e183605. [also cited in Ch. 34, 43]

Chapter 34. Exercise

Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. *Lancet* 2015;386:266-273. [also cited in Ch. 43, 45, 46]

Chapter 35. Sleep

McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. *N Engl J Med* 2016;375:919-931.

Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults. *Am J Epidemiol* 2013;177:1006-1014.

Chapter 36. Nutrition

Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. *J Am Med Dir Assoc* 2013;14:542-559.

Berry SE, Valdes AM, Drew DA, et al. Human postprandial responses to food and potential for precision nutrition. *Nat Med* 2020;26:964-973. [also cited in Ch. 48]

Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. *N Engl J Med* 2018;378:e34.

Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet* 2015;385:2255-2263. [also cited in Ch. 37, 43]

Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. *Cell* 2015;163:1079-1094. [also cited in Ch. 48]

Chapter 37. Mental Work

Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet* 2020;396:413-446. [also cited in Ch. 47]

Savin MJ, Wang H, Pei H, et al. Association of a pace of aging epigenetic clock with rate of cognitive decline in the Framingham Heart Study Offspring Cohort. *Alzheimers Dement (Amst)*. 2024;16(4):e70038. doi:10.1002/dad2.70038. [doi:10.1002/dad2.70038](https://doi.org/10.1002/dad2.70038) · [Source](#) [also cited in Ch. 47, 48]

Chapter 38. Hair Restoration

Penha MÁ, Miot HA, Kasprzak M, et al. Oral minoxidil 5 mg daily versus topical minoxidil 5% twice daily for male androgenetic alopecia: a randomized clinical trial. *JAMA Dermatol* 2024;160:600-605.

Chapter 39. Sexual Wellness

Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. *J Urol* 2013;190:199-207.

Chapter 40. Skin and Aesthetic Interventions

Hughes MCB, Williams GM, Baker P, Green AC. Sunscreen and prevention of skin aging: a randomized trial. *Ann Intern Med* 2013;158:781-790.

Kligman AM, Grove GL, Hirose R, Leyden JJ. Topical tretinoin for photoaged skin. *J Am Acad Dermatol* 1986;15:836-859.

Chapter 41. Bladder, Pelvic Floor, and Continence Rehabilitation

Brea-Gómez B, Pérez-Llanes R, Ortega-Donaire L, et al. Effectiveness of pelvic floor muscle training with biofeedback in patients undergoing radical prostatectomy: systematic review and meta-analysis. *Eur Urol Focus* 2025; published online ahead of print. [PMID 40318944](#) · [Source](#)

Flagged for editorial review — shown as supplied.

Lucente V, MacDiarmid S, Khera M, et al. Two-year results from a prospective, multicenter, single-arm pivotal study of an implantable tibial neuromodulation system for the treatment of urinary urgency incontinence. *Urology* 2024;186:80-87.

Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmIT trial. *J Urol* 2010;183:1438-1443.

Chapter 44. Early Intervention and the Minimally Invasive Framework

Bretthauer M, Løberg M, Wieszczy P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. *N Engl J Med* 2022;387:1547-1556. (NordICC trial.)

Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA). *Eur Heart J*. 2018;39:2401-2408. doi:10.1093/eurheartj/ehy217. doi:10.1093/eurheartj/ehy217 · [Source](#) [also cited in Ch. 46]

Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med* 2014;370:1287-1297. (Cologuard pivotal trial.)

Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. *N Engl J Med* 2013;369:1095-1105. [also cited in Ch. 46]

Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. *N Engl J Med*. 2019;380:1695-1705. doi:10.1056/NEJMoa1814052. doi:10.1056/NEJMoa1814052 · [Source](#)

Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. *N Engl J Med*. 2012;366:687-696. doi:10.1056/NEJMoa1100370. doi:10.1056/NEJMoa1100370 · [Source](#)

Chapter 46. Maintenance — The Long-Term Framework

Gong Q, Zhang P, Wang J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. *Lancet Diabetes Endocrinol*. 2019;7:452-461. doi:10.1016/S2213-8587(19)30093-2. doi:10.1016/S2213-8587(19)30093-2 · [Source](#)

Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. *Lancet*. 2006;368:1673-1679.

Chapter 47. The Lifespan Framework — Adaptation Across Demographics

Bell CG, Lowe R, Adams PD, et al. DNA methylation aging clocks: challenges and recommendations. *Genome Biol* 2019;20:249.

Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. *eLife* 2022;11:e73420. [also cited in Ch. 48]

Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. *Nat Rev Genet* 2018;19:371-384. [also cited in Ch. 48]

Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol* 2013;14:R115. [also cited in Ch. 48]

Lehallier B, Gate D, Schaum N, et al. Undulating changes in human plasma proteome profiles across the lifespan. *Nat Med* 2019;25:1843-1850. [also cited in Ch. 48]

Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY)* 2018;10:573-591. (PhenoAge.) [also cited in Ch. 48]

Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging (Albany NY)* 2019;11:303-327.

Chapter 48. The Future of Comprehensive Practice

Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. *Mol Cell* 2013;49:359-367.

General & Cross-Cutting References

Chapter assignment pending editorial confirmation; preserved exactly as supplied.

Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing*. 2019;48:16-31. Correction: *Age Ageing*. 2019;48:601. doi:10.1093/ageing/afy169. doi:10.1093/ageing/afy169 · Source

Dietary Supplement Health and Education Act of 1994, Pub L No. 103-417, 108 Stat 4325 (codified at 21 USC §§ 321 et seq.).

Food and Drug Administration. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol (Lipfendra). News release, 2026. Source

Food and Drug Administration. FDA approves treatment for metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. News release, 2025; ongoing accelerated-approval confirmatory study status accessed August 13, 2026. Source

Harman D. Aging: a theory based on free radical and radiation chemistry. *J Gerontol* 1956;11:298-300.

MESA Investigators — see Budoff MJ et al. (above) for the contemporary CAC-mortality framework citation.

Nadon NL, Strong R, Miller RA, Harrison DE. NIA Interventions Testing Program: investigating putative aging intervention agents in a genetically heterogeneous mouse model. *eBioMedicine* 2017;21:3-4.

Nobel Assembly at Karolinska Institutet. The Nobel Prize in Physiology or Medicine 2009: Elizabeth H. Blackburn, Carol W. Greider and Jack W. Szostak. October 5, 2009. [Source](#)

Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. *JAMA*. 2003;289:2083-2093.
doi:10.1001/jama.289.16.2083. doi:10.1001/jama.289.16.2083 · [Source](#)

Paulescu NC. Recherche sur le rôle du pancréas dans l'assimilation nutritive. *Arch Int Physiol* 1921;17:85-103.